A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
INTEGRATED DIAGNOSTICS HOLDINGS operates in the Medical - Diagnostics & Research industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 129M | 129M | 134M | 188M | 333M |
| Net Income | 24M | 24M | 17M | 27M | 95M |
| EPS | $0.04 | $0.04 | $0.03 | $0.05 | $0.15 |
| Free Cash Flow | 31M | 31M | 7.2M | -4.7M | 129M |
| ROIC | 57.0% | 37.7% | 15.4% | 19.7% | 61.2% |
| Gross Margin | 38.1% | 38.1% | 37.0% | 40.6% | 53.7% |
| Debt/Equity | 0.00 | 0.10 | 0.04 | 0.57 | 0.39 |
| Dividends/Share | $0.00 | $0.00 | - | $0.01 | $0.00 |
| Operating Income | 27M | 27M | 24M | 43M | 144M |
| Operating Margin | 21.2% | 21.2% | 17.9% | 23.1% | 43.3% |
| ROE | 39.8% | 32.8% | 15.5% | 17.9% | 53.4% |
| Shares Outstanding | 592M | 592M | 600M | 585M | 635M |
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 333M | 188M | 134M | 129M | 129M |
| Gross Margin | 53.7% | 40.6% | 37.0% | 38.1% | 38.1% |
| R&D | N/A | N/A | N/A | N/A | N/A |
| SG&A | 35M | 33M | 26M | 22M | 22M |
| EBIT | 144M | 43M | 24M | 27M | 27M |
| Op. Margin | 43.3% | 23.1% | 17.9% | 21.2% | 21.2% |
| Net Income | 95M | 27M | 17M | 24M | 24M |
| Net Margin | 28.6% | 14.6% | 12.4% | 18.8% | 18.8% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||
| ROIC | 61.2% | 19.7% | 15.4% | 37.7% | 57.0% |
| ROE | 53.4% | 17.9% | 15.5% | 32.8% | 39.8% |
| ROA | 23.9% | 8.1% | 7.2% | 14.0% | 15.1% |
| Cash Flow | |||||
| Op. Cash Flow | 145M | 11M | 18M | 35M | 35M |
| Free Cash Flow | 129M | -4.7M | 7.2M | 31M | 31M |
| Owner Earnings | 145M | 10M | 17M | 35M | 35M |
| CapEx | 16M | 16M | 11M | 4.7M | 4.7M |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | N/A | 4.7M |
| D&A | 0 | 0 | 0 | 0 | 0 |
| CapEx/OCF | 11.2% | 143.6% | 59.5% | 13.3% | 13.3% |
| Capital Allocation | |||||
| Dividends Paid | 31M | 73M | 0 | 620K | 620K |
| Dividend Yield | 64.4% | 244.9% | N/A | 12.7% | 0.2% |
| Share Buybacks | 0 | 0 | 0 | 8.5M | 8.5M |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 160.6% | 2.3% |
| Stock-Based Comp | 55K | 395K | 231K | 106K | 106K |
| Debt Repayment | 1.6M | 1.1M | 2.5M | 792K | 792K |
| Balance Sheet | |||||
| Net Debt | 13M | 38M | -18M | -21M | -27M |
| Cash & Equiv. | 57M | 34M | 22M | 27M | 27M |
| Long-Term Debt | N/A | N/A | 2.2M | 915K | 915K |
| Debt/Equity | 0.39 | 0.57 | 0.04 | 0.10 | 0.00 |
| Interest Coverage | 15.8 | 6.1 | 4.6 | 6.2 | 6.2 |
| Equity | 178M | 127M | 87M | 61M | 61M |
| Total Assets | 398M | 276M | 188M | 161M | 161M |
| Total Liabilities | 220M | 148M | 87M | 82M | 82M |
| Intangibles | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | 99M | 41M | 42M | 41M | 41M |
| Working Capital | 44M | 8.3M | 22M | 21M | 21M |
| Current Assets | 194M | 85M | 64M | 70M | 70M |
| Current Liabilities | 150M | 76M | 41M | 49M | 49M |
| Per Share Data | |||||
| EPS | 0.15 | 0.05 | 0.03 | 0.04 | 0.04 |
| Owner EPS | 0.23 | 0.02 | 0.03 | 0.06 | 0.06 |
| Book Value | 0.28 | 0.22 | 0.15 | 0.10 | 0.10 |
| Cash Flow/Share | 0.23 | 0.02 | 0.03 | 0.06 | 0.04 |
| Dividends/Share | 0.00 | 0.01 | N/A | 0.00 | 0.00 |
| Shares Out. | 635.1M | 585.1M | 600.4M | 592.0M | 592.0M |
| Valuation | |||||
| P/E Ratio | 0.6 | 0.6 | 0.4 | 0.2 | 15.2 |
| P/FCF | 0.4 | N/A | 1.0 | 0.2 | 12.1 |
| EV/EBIT | 0.5 | 1.2 | -0.5 | -0.6 | 12.5 |
| Price/Book | 0.3 | 0.1 | 0.1 | 0.1 | 6.1 |
| Price/Sales | 0.2 | 0.1 | 0.1 | 0.0 | 2.9 |
| FCF Yield | 243.5% | -30.3% | 101.1% | 583.0% | 8.3% |
| Market Cap | 53M | 16M | 7.1M | 5.3M | 371M |
| Avg. Price | 0.07 | 0.05 | 0.02 | 0.01 | 0.63 |
| Year-End Price | 0.08 | 0.03 | 0.01 | 0.01 | 0.63 |
INTEGRATED DIAGNOSTICS HOLDINGS passes 4 of 9 quality checks, suggesting mixed fundamentals.
INTEGRATED DIAGNOSTICS HOLDINGS trades at 15.2x trailing earnings, compared to its 15-year median P/E of 0.5x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 12.1x vs a median of 0.4x. The company's 5-year average ROIC is 33.5% with a gross margin of 42.3%. Total shareholder yield (dividends + buybacks) is 2.4%. At current prices, the estimated annualized return to fair value is -33.5%.
INTEGRATED DIAGNOSTICS HOLDINGS (IDHC-L) has a current P/E ratio of 15.2, compared to its historical median P/E of 0.5. The stock is currently considered Expensive based on its historical valuation range.
INTEGRATED DIAGNOSTICS HOLDINGS (IDHC-L) has a 5-year average return on invested capital (ROIC) of 33.5%. This indicates strong capital allocation and a potential competitive advantage.
INTEGRATED DIAGNOSTICS HOLDINGS (IDHC-L) has a market capitalization of $371M. It is classified as a small-cap stock.
Yes, INTEGRATED DIAGNOSTICS HOLDINGS (IDHC-L) pays a dividend with a trailing twelve-month yield of 0.17%. The company also returns capital through share buybacks, with a buyback yield of 2.28%.
Based on historical P/E analysis, INTEGRATED DIAGNOSTICS HOLDINGS (IDHC-L) appears expensive. The current P/E of 15.2 is 3004% above its historical median of 0.5. The estimated fair value CAGR (P/E method) is -24.5%.
INTEGRATED DIAGNOSTICS HOLDINGS (IDHC-L) operates in the Medical - Diagnostics & Research industry, within the Healthcare sector.
INTEGRATED DIAGNOSTICS HOLDINGS (IDHC-L) reported annual revenue of $129 million in its most recent fiscal year, based on SEC EDGAR filings.
INTEGRATED DIAGNOSTICS HOLDINGS (IDHC-L) has a net profit margin of 18.8%. This is a healthy margin.
INTEGRATED DIAGNOSTICS HOLDINGS (IDHC-L) generated $31 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
INTEGRATED DIAGNOSTICS HOLDINGS (IDHC-L) has a debt-to-equity ratio of 0.10. This indicates a conservatively financed balance sheet.
INTEGRATED DIAGNOSTICS HOLDINGS (IDHC-L) reported earnings per share (EPS) of $0.04 in its most recent fiscal year.
INTEGRATED DIAGNOSTICS HOLDINGS (IDHC-L) has a return on equity (ROE) of 32.8%. This indicates the company generates strong returns for shareholders.
INTEGRATED DIAGNOSTICS HOLDINGS (IDHC-L) has a 5-year average gross margin of 42.3%. This indicates decent pricing power.
The Ledger Terminal provides 4 years of financial data for INTEGRATED DIAGNOSTICS HOLDINGS (IDHC-L), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
INTEGRATED DIAGNOSTICS HOLDINGS (IDHC-L) has a book value per share of $0.10, based on its most recent annual SEC filing.
No recent press releases.